{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:37:57Z","timestamp":1786995477733,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012633","name":"Royal North Shore Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.pathol.2019.10.010","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T20:06:51Z","timestamp":1577995611000},"page":"271-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Unique and distinctive histological features of immunotherapy-related thyroiditis"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-9236","authenticated-orcid":false,"given":"Matthew","family":"Zaborowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sywak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Nyl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9212-6927","authenticated-orcid":false,"given":"Angela","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2019.10.010_bib1","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.otc.2017.04.006","article-title":"Immunotherapy: who is eligible","volume":"50","author":"Wang","year":"2018","journal-title":"Otolaryngol Clin North Am"},{"key":"10.1016\/j.pathol.2019.10.010_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.pathol.2019.10.010_bib3","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3390\/ijms20061405","article-title":"PD-1 ligand expression in epithelial thyroid cancers: potential clinical implications","volume":"20","author":"Ulisse","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pathol.2019.10.010_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13578-018-0232-4","article-title":"Tumour cells versus host immune cells: whose PD-L1 contributes to PD-1\/PD-L1 blockade mediated cancer immunotherapy?","volume":"8","author":"Tang","year":"2018","journal-title":"Cell Biosci"},{"key":"10.1016\/j.pathol.2019.10.010_bib5","doi-asserted-by":"crossref","first-page":"102285","DOI":"10.1016\/j.jaut.2019.05.013","article-title":"Analysis of the PD-1\/PD-L1 axis in autoimmune thyroid disease: insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity","volume":"103","author":"Alvarez-Sierra","year":"2019","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.pathol.2019.10.010_bib6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2019.10.010_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12902-018-0267-x","article-title":"Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma","volume":"18","author":"Yano","year":"2018","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.pathol.2019.10.010_bib8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12022-019-9579-2","article-title":"Pembrolizumab-induced thyroiditis","volume":"30","author":"Imblum","year":"2019","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.pathol.2019.10.010_bib9","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibitory therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.pathol.2019.10.010_bib10","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1089\/thy.2018.0418","article-title":"Histology of nivolumab-induced thyroiditis","volume":"28","author":"Neppl","year":"2018","journal-title":"Thyroid"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302519304441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302519304441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:25:30Z","timestamp":1758471930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302519304441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0031302519304441"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2019.10.010","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unique and distinctive histological features of immunotherapy-related thyroiditis","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2019.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia. All rights reserved.","name":"copyright","label":"Copyright"}]}}